Overview

This trial is active, not recruiting.

Condition diabetic macular edema
Treatment ranibizumab
Phase phase 2/phase 3
Target VEGF
Sponsor The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
Start date May 2008
End date May 2011
Trial size 40 participants
Trial identifier NCT00885794, EK 08-069-0508

Summary

Diabetic maculopathy is the leading cause of visual impairment in the working-age population in developed countries. Diabetic macular edema can cause impaired visual acuity and so far is treated by laser, vitreous surgery, and intravitreal cortisone application. Still 50% of the cases do not respond to the treatment.

Recently intraocular anti-VEGF-treatment with ranibizumab (Lucentis®, Novartis) in diabetic macular edema has proven efficacy to last over a period of 3 to 6 months. Still, the optimal dosage for those intravitreal injections still has to be found, because frequent injections are necessary.

The measurement of visual acuity is inadequate to quantify in detail the visual impairment. Using the newest technology of a high-definition optical coherence tomography (Cirrus-OCT, Carl Zeiss Meditec Inc.) to determine the retinal thickness, and a miroperimetry (MP-1, Nidek Technologies) to determine retinal sensitivity, we hope to find the optimal dosage of intravitreal anti-VEGF treatment in diabetic macular edema.

Study objective: To determine the dose response of 0.5mg and 1.0mg ranibizumab (Lucentis®, Novartis Pharma) intravitreal injection in subjects with resistant diabetic macular edema and evaluate safety and tolerability.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking single blind (investigator)
Primary purpose treatment
Arm
(Experimental)
3 intravitreal injections of 0.5 mg Ranibizumab every 5 weeks
ranibizumab Lucentis
3 intravitreal injection every 5 weeks
(Experimental)
3 intravitreal injections of 1.0mg Ranibizumab every 5 weeks
ranibizumab Lucentis
3 intravitreal injection every 5 weeks

Primary Outcomes

Measure
Retinal thickness
time frame: at 3 months

Secondary Outcomes

Measure
Retinal sensitivity
time frame: 3, 6, and 9 months
Distance best corrected visual acuity
time frame: 3, 6, and 9 months
Reading best corrected visual acuity
time frame: 3, 6, and 9 months
Intraocular pressure
time frame: 3, 6, and 9 months
Type of diabetic macular edema
time frame: 3, 6, and 9 months
Type of diabetes mellitus HbA1c
time frame: 3, 6, and 9 months
Blood-pressure
time frame: 3, 6, and 9 months
Age
time frame: 3, 6, and 9 months

Eligibility Criteria

Male or female participants at least 51 years old.

Inclusion Criteria: - Study eye with clinically significant macular edema, for which one of the following characteristics has to be present: - retinal thickening at or within 500µm from the center of the macula, - hard exudates at or within 500µm from the center of the macula associated with thickening of the adjacent retina, - a zone (>1-disk area) or zones of retinal thickening of which any part is within 1 disk diameter from the center of the macula. - Second line treatment after ineffective laser treatment - Men or women with diabetes mellitus - Only one eye per patient - Age > 50 years - HbA1c < 8% Exclusion Criteria: - Study eye with concomitant retinal or choroidal disorder other than diabetic retinopathy - Study eye with significant central lens opacities and / or conditions that limit the view of the fundus - poor general condition - woman of childbearing potential, current pregnancy or breastfeeding - Patients who are unwilling to adhere to visit examination schedules - Evidence of macular traction or taut posterior hyloid.

Additional Information

Official title Microperimetry and High-Definition-OCT in Ranibizumab Treatment for Diabetic Macular Edema (MORE-Study)
Principal investigator Ulrike Stolba, MD
Description Diabetic maculopathy due to diabetic macular edema (DME) is the leading cause of visual impairment in the working-age population in developed countries. DME is the swelling of the retina resulting from the exudation and accumulation of extracellular fluid and proteins in the macula. Structural changes in the endothelium of retinal vessels lead to a breakdown of the blood-retina barrier and increase vascular permeability, resulting in exudation. The standardized treatment of DME is a focal laser or GRID-laser treatment with or without combined triamcinolone intravitreal injections. Those laser treatments produce scars in the central retina and are not always very effective. In cases of macular traction or taut posterior hyloid vitrectomy and retinal surgery are necessary. Vascular endothelial growth factor (VEGF) has been implicated as an important factor in the occurrence of vascular permeability in DME. In patients with DME, VEGF levels are significantly elevated, compared to patients without ocular disease. Therefore, anti-VEGF treatment has been implicated as an important treatment of DME and recently intraocular anti-VEGF-treatment with ranibizumab (Lucentis®, Novartis Pharma) in diabetic macular edema has proven to be very effective. Just like in patients with age-related macular degeneration (AMD), anti-VEGF treatment was given 3 times every 4-6 weeks. The same treatment was repeated at a relapse of the disease, again 3 times every 4-6 weeks. One study group treated DME with 0.5mg ranibizumab intravitreal injections and the other compared 0.3mg to 0.5mg of ranibizumab intravitreal injections. An optimal treatment dose has not been found yet. Visual acuity assessment is currently used to determine the functional damage caused by edema, although it may not completely describe the functional condition of the patient. Furthermore, visual acuity alone does not seem to be the best parameter to define the effect and continuation of treatment. Retinal thickness, as measured by the noninvasive optical coherence tomography (OCT) can deliver detailed information about the retinal situation during and after treatment. Also a fundus related perimetry, known as microperimetry (MP), is a useful noninvasive examination method in determining the site of relative and absolute scotomas and also fixation characteristics. With MP the macular sensitivity can be measured to further assess the macular condition. Using the newest technology of a high-definition OCT (Cirrus-OCT, Carl Zeiss Meditec Inc.) to determine the retinal thickness, and a MP with automated correction for eye movements (MP-1, Nidek Technologies) to determine retinal sensitivity, we intend to analyze this new treatment option for DME, and find the optimized dose for intravitreal injection of ranibizumab in cases of ineffective laser treatment.
Trial information was received from ClinicalTrials.gov and was last updated in June 2011.
Information provided to ClinicalTrials.gov by The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery.